This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neuromyelitis optica (Devic disease, NMOSD)Neuromyelitis Optica Spectrum Disorder (NMOSD / Devic Disease)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G36.0 | Special Copayment Reduction: V276 | Coverage period: 5 years
B. SynonymsNeuromyelitis optica, Devic disease, Devic syndrome, neuromyelitis optica spectrum disorder, NMOSD, Neuromyelitis optica (NMO), NMO spectrum disorder, AQP4-IgG-positive NMOSD, spectrum with MOG-IgG-associated disease (MOGAD)
C. Adult onsetLikelihood of first onset in adulthood very high — mean age of onset 32–41 years; AQP4-IgG-positive NMOSD has a female predominance (F:M ≈ 9:1); MOG-IgG-positive disease occurs in both children and adults
1. History1. History
2. Causes2. Causes
3. Genetics3. Genetics
4. Epidemiology4. General epidemiology
5. Pathophysiology5. Pathophysiology
6. Symptoms6. Symptoms
7. Signs7. Signs
8. Screening8. Screening
9. Diagnosis9. Diagnosis
10. Treatment10. Treatment
11. Prognosis11. Prognosis
12. Prevention12. Prevention
13. References13. References

1. History

Clinical descriptions of neuromyelitis optica (NMO) date back to the 19th century. In the 1870s, Edward Moxon in England reported a case of demyelinating disease involving the optic nerve and spinal cord simultaneously, and in 1894 the French neurologist Eugène Devic (1858–1930) and his student Fernand Gault compiled 16 cases of optic neuritis accompanied by myelitis, systematically described them as a single clinical syndrome, and named it "neuromyélite optique aiguë". It subsequently came to be called "Devic disease" or "Devic syndrome" after Devic.

For most of the 20th century, NMO was regarded as a subtype or variant of MS. However, when Brian Weinshenker's research team at the Mayo Clinic discovered an autoantibody against aquaporin-4 (AQP4)—AQP4-IgG (NMO-IgG)—in 2004 and published it in Lancet, NMO was established as an independent autoantibody-mediated disease separate from MS. This discovery brought a paradigm shift in understanding the pathogenesis of NMOSD and in developing therapeutic targets. In 2006 Wingerchuk et al. presented revised NMO diagnostic criteria, and in 2015 the International Panel for NMO Diagnosis (IPND) published comprehensive NMOSD diagnostic criteria centered on AQP4-IgG antibody status, which are still applied today. Since 2015, MOG (myelin oligodendrocyte glycoprotein)-IgG-associated disease (MOGAD) has been classified as a separate antibody-mediated disease in some AQP4-negative NMOSD.

2. Causes

NMOSD is an autoimmune disease mediated by autoantibodies targeting the aquaporin-4 (AQP4) water channel protein or myelin oligodendrocyte glycoprotein (MOG) in the CNS.

AQP4-IgG-positive NMOSD

Accounts for about 70–80% of all NMOSD. AQP4 is a water channel protein expressed at high concentrations in the end-feet of astrocytes and is particularly abundant at the blood–brain barrier (BBB), the cerebrospinal fluid interface, the optic nerve, and the spinal cord. AQP4-IgG of the IgG1 subclass binds to the AQP4 M23 isoform and causes severe demyelination and necrosis through complement activation, influx of NK cells, eosinophils, and neutrophils, and destruction of astrocytes.

MOG-IgG-positive NMOSD (MOGAD)

Accounts for a substantial portion (20–40%) of AQP4-IgG-negative NMOSD. MOG is a glycoprotein expressed on oligodendrocytes and the outermost layer of myelin; after binding, MOG-IgG (mainly IgG1) damages myelin and oligodendrocytes through complement and Fc-dependent pathways. MOGAD is recognized as an independent disease spectrum distinct from AQP4+ NMOSD and MS in its clinical, imaging, and prognostic features.

Double-seronegative NMOSD

Cases negative for both AQP4-IgG and MOG-IgG, accounting for about 5–10% of the total. Additional antibodies not yet identified (such as GFAP-IgG) or limitations of diagnostic techniques may be involved.

3. Genetics

Unlike MS, NMOSD is not a simple Mendelian genetic disease, and the concordance rate in monozygotic twins is also low, suggesting a complex interaction of environmental and genetic factors. However, familial cases sharing an autoimmune predisposition are rarely reported.

HLA-related associations

In AQP4-IgG-positive NMOSD, HLA-DRB1*03:01 and HLA-DPB1*05:01 have been reported as risk alleles in multiple cohorts. In East Asian populations (Korea, Japan, China), HLA-DPB1*05:01 shows a particularly strong association. In contrast, specific HLA risk alleles are less clearly identified in MOG-IgG-positive NMOSD.

Non-HLA genetic factors

GWAS studies of NMOSD are smaller in scale than those of MS, so no clear conclusions have yet been drawn. There is currently no evidence that variants of the AQP4 gene (4q11) itself are directly associated with NMOSD risk. The possibility that the common genetic background of autoimmune diseases (PTPN22, STAT4, IRF5, etc.) is partly shared in NMOSD is being studied.

Associated autoimmune diseases

About 30–40% of patients with AQP4+ NMOSD have another accompanying autoimmune disease. Systemic lupus erythematosus (SLE), Sjögren syndrome, rheumatoid arthritis, myasthenia gravis, and autoimmune thyroid disease are the most common. The presence of these accompanying autoimmune diseases suggests a genetic autoimmune predisposition.

4. General epidemiology

The worldwide prevalence of NMOSD is estimated at about 0.5–4 per 100,000 population, lower than that of MS. Prevalence is relatively high in non-white populations in East Asia, South America, Africa, and elsewhere, and in regions where MS prevalence is low, NMOSD tends to account for a substantial proportion of demyelinating diseases.

The mean age of onset in AQP4+ NMOSD is about 32–41 years, somewhat later than the typical age of onset of MS. It can also occur in children and the elderly (aged 60 or older). The sex ratio in AQP4+ NMOSD shows a marked female predominance of female : male ≈ 9:1, much higher than the 3:1 of MS. In MOG-IgG-positive NMOSD, the sex difference is relatively small (F:M ≈ 1.5:1).

In Korea, the phenotypic distinction between MS and NMOSD was studied relatively early, and since the 2000s the clinical characteristics of Korean patients with NMOSD (relapse frequency, antibody positivity rate, treatment response) have been documented through domestic cohort studies. The AQP4-IgG positivity rate in Korean patients with NMOSD is reported at about 70–80%, similar to Western reports. Clinical patterns of older age at onset, long spinal cord lesions, and recurrent optic nerve involvement are also commonly observed in Korean patients.

5. Pathophysiology

The core of the pathophysiology of AQP4+ NMOSD is a humoral autoimmune mechanism centered on astrocyte injury by AQP4-IgG.

AQP4-IgG-mediated pathology

AQP4-IgG (IgG1) produced by AQP4-reactive plasma cells (plasmablasts/plasma cells) in peripheral lymph nodes reaches the CNS via the bloodstream. After binding to astrocyte end-feet, where AQP4 is expressed at high concentrations, injury proceeds through the following pathways.

Astrocyte injury causes loss of the excitatory amino acid transporter (EAAT2; glutamate transporter), secondarily causing oligodendrocyte and neuronal injury through glutamate excitotoxicity. For this reason, unlike MS, the pathological findings of NMOSD tend to show severe destruction not only of myelin but also of axons and neurons.

MOG-IgG-mediated pathology (MOGAD)

MOG-IgG binds to MOG on the outer layer of myelin and causes myelin damage through complement activation and ADCC, but oligodendrocyte injury predominates over astrocyte injury, so the pathology partly resembles MS but differs in distribution and severity. MOGAD commonly has a relapsing course, but the prognosis is often relatively better than in AQP4+ NMOSD.

6. Symptoms

NMOSD is characterized by severe acute attacks that selectively involve mainly the optic nerve and spinal cord. Disability accumulates because of incomplete recovery after each attack.

Optic Neuritis (ON)

Acute Myelitis

Other clinical symptoms (brain and brainstem involvement)

7. Signs

Objective signs identifiable on neurological examination vary with the site of involvement.

Ophthalmic signs

Spinal cord signs

Brainstem and other signs

8. Screening

Early differentiation of NMOSD from MS is clinically very important because treatment strategies are fundamentally different. Some MS drugs (natalizumab, fingolimod, IFN-β, etc.) can actually worsen NMOSD relapses, so failure to differentiate can lead to serious consequences.

Serum AQP4-IgG testing

The cell-based assay (CBA) is recommended as the most sensitive and specific method (sensitivity about 70–80%, specificity >99%). ELISA has a high false-negative rate and is not recommended as the initial test. If AQP4-IgG is negative, an MOG-IgG CBA is additionally performed. Antibody titers may be partly associated with disease activity but are not sufficient as a sole indicator of treatment response.

MRI screening findings

MRI findings suggestive of NMOSD are key to differentiation from MS.

Other screening tests

On cerebrospinal fluid testing, the combination of neutrophilic pleocytosis, high protein levels, and negative OCBs is more consistent with NMOSD than MS. Visual evoked potential (VEP) abnormalities are nonspecific but are adjunctive in confirming optic nerve lesions. ANA, anti-Ro/La, anti-dsDNA, and rheumatoid factor tests are performed in parallel to screen for accompanying autoimmune diseases (lupus, Sjögren).

9. Diagnosis

The NMOSD diagnostic criteria of the 2015 International Panel for NMO Diagnosis (IPND) are currently used as the standard.

Summary of the 2015 IPND NMOSD diagnostic criteria

ItemCriteria
AQP4-IgG positiveDiagnosis is established with ≥1 of the following 6 core clinical characteristics and exclusion of other diseases
① optic neuritis ② acute myelitis ③ area postrema syndrome ④ acute brainstem syndrome ⑤ symptomatic narcolepsy or diencephalic syndrome ⑥ symptomatic cerebral syndrome
AQP4-IgG negative or not tested≥2 of the above core clinical characteristics (≥1 must be ①, ②, or ③) + additional MRI requirements met (LETM, specific brain MRI patterns, etc.), exclusion of other diseases

Differential diagnosis

10. Treatment

Treatment of NMOSD is broadly divided into ① treatment of acute attacks and ② prevention of relapse (long-term immunosuppressive treatment). Unlike MS, NMOSD far more commonly has a relapsing course than a monophasic course, and irreversible disability accumulates with each relapse, so aggressive long-term preventive treatment is essential.

Treatment of acute attacks

High-dose methylprednisolone (IVMP): intravenous administration of 1,000 mg/day × 3–7 days is the first-line acute treatment. Steroids suppress inflammation and rapidly restore BBB function but do not guarantee complete recovery. Gradual tapering with oral prednisolone is generally carried out after steroid administration.

Plasma Exchange (PLEX): in severe attacks that do not respond sufficiently to IVMP (severe loss of vision, complete paralysis, etc.), performing 5–7 sessions of PLEX (every other day) early increases the likelihood of functional recovery. The mechanism of direct removal of AQP4-IgG antibodies is the rationale for treatment. It can be performed together with IVMP or alone after IVMP failure. Retrospective study results are accumulating that early PLEX shows a significant benefit for visual recovery in severe optic neuritis.

Intravenous immunoglobulin (IVIG): may be considered as an alternative when PLEX is not possible or access is limited, but the level of evidence is limited.

Long-term relapse prevention — FDA/EMA-approved biologics

Between 2019 and 2020, three monoclonal antibodies received FDA approval for AQP4+ NMOSD, fundamentally changing the NMOSD treatment paradigm.

Eculizumab (Soliris): a monoclonal antibody inhibiting terminal complement C5. FDA approved in June 2019 (adult AQP4-IgG-positive NMOSD). In the phase 3 PREVENT trial, a very strong relapse-suppressing effect was confirmed, with a 94% reduction in relapse risk versus placebo (HR 0.06, p<0.0001). Regimen: 900 mg IV once weekly × 4 weeks loading, then 1,200 mg IV every 2 weeks maintenance. Main precautions: increased risk of meningococcal infection (quadrivalent meningococcal vaccination and prophylactic antibiotics before treatment are mandatory). Treatment cost is very high. Ravulizumab (Ultomiris) is a long-half-life C5 inhibitor derived from eculizumab, given once every 8 weeks, and its approval was extended to the NMOSD indication in 2023.

Inebilizumab (Uplizna): a humanized anti-CD19 monoclonal antibody targeting CD19⁺ B cells (including plasma cells and plasmablasts). FDA approved in June 2020. In the phase 3 N-MOmentum trial, relapse risk was reduced by 73% versus placebo. Efficacy was better in AQP4+ patients. CD19 is expressed on a broader B-cell lineage than CD20 (extending to plasma cells), so it can more effectively eliminate AQP4-IgG-producing plasma cells. Regimen: 300 mg IV loading at a 2-week interval (2 doses), then maintenance once every 6 months. Main adverse effects: urinary tract infection, infusion reactions, decreased IgG.

Satralizumab (Enspryng): a recycling monoclonal antibody against the interleukin-6 receptor (IL-6R) (recycling antibody technology). FDA approved in August 2020. In the phase 3 SAkuraSky (combined with immunosuppressants) and SAkuraStar (monotherapy) trials, relapse risk was reduced by 62% and 79%, respectively, in AQP4+ patients. Self-administration is possible by subcutaneous injection (satralizumab 120 mg SC at weeks 0, 2, and 4, then once every 4 weeks). IL-6 is a cytokine that promotes plasma cell differentiation and AQP4-IgG production, and IL-6R blockade is the therapeutic mechanism. Can be used in adolescents aged 12 or older (FDA approved). Main adverse effects: injection-site reactions, elevated liver enzymes, elevated lipids, infections.

Nonbiologic immunosuppressive treatment (conventional treatment)

These agents have been used since before the introduction of the above new biologics and are still used for reasons of access and cost.

Specific considerations for MOGAD treatment

MOG-IgG-positive NMOSD (MOGAD) is more steroid-responsive than AQP4+ NMOSD, but steroid-dependent relapses are frequent. A protocol of slowly tapering oral prednisolone over several months after high-dose IVMP is recommended. For long-term immunosuppression, azathioprine, MMF, and repeated IVIG are used, but eculizumab, inebilizumab, and satralizumab do not guarantee the same efficacy in MOGAD, so caution is needed with off-label use.

11. Prognosis

The prognosis of NMOSD was very poor in the pre-treatment era. Natural history studies indicate that within 5 years after the first attack, about 50% may become functionally blind in at least one eye or unable to walk independently. Unlike MS, neurological disability in NMOSD hardly progresses in the intervals between relapses and shows a 'relapse-dependent' pattern in which disability accumulates stepwise with relapses. Therefore, prevention of relapse is key to improving prognosis.

With the recent spread of new biologics (eculizumab, inebilizumab, satralizumab) and rituximab, relapse suppression rates have markedly improved, making it possible to minimize long-term accumulation of disability in patients receiving appropriate treatment. Persistent AQP4-IgG antibody positivity, female sex, repeated involvement of spinal cord lesions, and incomplete motor recovery are poor prognostic factors. MOG-IgG-positive NMOSD generally has a better prognosis than AQP4+ NMOSD, and complete recovery sometimes occurs, but the prognosis worsens with repeated relapses.

The most important causes of death are respiratory muscle paralysis due to severe cervical myelitis, aspiration pneumonia, and respiratory failure. Early admission to the intensive care unit and mechanical ventilation support are decisive for survival in the acute phase.

12. Prevention

There is currently no primary prevention for NMOSD, but secondary prevention (relapse prevention) strategies after confirmation of the diagnosis are key to preventing accumulation of disability.

Prompt initiation of immunosuppressive treatment

Long-term relapse prevention treatment should be started immediately upon confirmation of AQP4+ NMOSD. Early initiation of treatment after the first attack most effectively lowers the risk of relapse, and because disability accumulates faster the shorter the interval between attacks, it is important to start treatment without diagnostic delay. If AQP4-IgG positivity is confirmed at the CIS stage, preventive treatment is considered before the second attack.

Avoidance of MS drugs

Natalizumab, fingolimod, alemtuzumab, and IFN-β are contraindicated in AQP4+ NMOSD because cases of worsened relapses have been reported in patients with NMOSD. Therefore, in patients presumed to have a demyelinating disease, AQP4-IgG/MOG-IgG status must be confirmed before starting treatment.

Infection prevention and vaccination

Patients receiving complement inhibitors (eculizumab, ravulizumab) are vulnerable to infections with encapsulated organisms (meningococcus, pneumococcus, Haemophilus). Quadrivalent meningococcal vaccination (MCV4) 2 weeks before starting treatment is mandatory, and when urgent treatment is already required, prophylactic antibiotics (penicillin V or amoxicillin) are given concurrently. Influenza and pneumococcal vaccines are given annually and regularly. During B-cell depletion therapy (rituximab, inebilizumab), live vaccines are contraindicated, and hepatitis B antigen/antibody status is checked before treatment, with vaccination completed in those who are negative.

Rehabilitation and quality-of-life management

Early rehabilitation after an attack (physical therapy, occupational therapy, gait training) is essential to maximize functional recovery. Ongoing management of accompanying symptoms such as spasticity, pain, bladder dysfunction, and depression is important for maintaining patients' quality of life and treatment adherence. Psychological support and patient education (early recognition of relapse, education on pathways to medical access for early high-dose steroid administration) are also components of secondary prevention.

13. References